参考文献/References:
[1]周梦茹,车振勇,高重阳,等,miRNA-128、miRNA-101在脑胶质瘤中的表达及意义[J],癌症进展,2020,18(19):2022-2025. [2]Xiao M,Li J,Li W,et al.MicroRNAs activate gene transcription epigenetically as an enhancer trigger[J].RNA Biol,2017,14(10):1326-1334. [3]Rupaimoole R,Calin GA,Lopez-Berestein G,et al.miRNA Deregulation in Cancer Cells and the Tumor Microenvironment[J].Cancer Discovery,2016,6(3):235-246. [4]Jing N,Yin L,Sun J,et al.Expression levels of miR-205 and miR-506 in colon cancer tissues and their relationships with clinicopathological features[J].Oncol Lett,2018,16(4):4331-4336. [5]Yin CY,Kong W,Jiang J,et al.miR-7-5p inhibits cell migration and invasion in glioblastoma through targeting SATB1[J].Oncol Lett,2019,17(2):1819-1825. [6]Zhang L,Liu L,Xu X,et al.miR-205/RunX2 axis negatively regulates CD44(+)/CD24(-) breast cancer stem cell activity[J].Am J Cancer Res,2020,10(6):1871-1887. [7]Duan B,Guo T,Sun H,et al.miR-205 as a biological marker in non-small cell lung cancer [J].Biomed Pharmacother,2017(91):823-830. [8]Qin RF,Zhang J,Huo HR,et al.MiR-205 mediated APC regulation contributes to pancreatic cancer cell proliferation[J].World J Gastroenterol,2019,25(28):3775-3786. [9]Li X,Li Y,Han Y,et al.miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1[J].Cancer Biother Radiopharm,2020,35(5):338-344. [10]Chen W,Kong KK,Xu XK,et al.Downregulation of miR-205 is associated with glioblastoma cell migration,invasion,and the epithelial-mesenchymal transition,by targeting ZEB1 via the Akt/mTOR signaling pathway[J].International Journal of Oncology,2018,52(2):485-495. [11]Zhu D,Tu M,Zeng B,et al.Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2[J].Cancer Medicine,2017,6(2):452-462. [12]贺文财.脑胶质瘤患者应用三维适形放疗的效果分析及对生存期的影响[J].中西医结合心血管病电子杂志,2020,8(1):34,40. [13]王竹,杨丽艳,刘圆圆,等.γH2AX和53BP1蛋白在肺正常上皮细胞DNA氧化损伤反应中的表达[J].临床检验杂志,2018,36(2):142-147.
相似文献/References:
[1]吴 刚,袁华兵.阿瑞匹坦对于改善Ⅲ~Ⅳ期颅内胶质瘤患者CINV的研究[J].医学信息,2019,32(13):87.[doi:10.3969/j.issn.1006-1959.2019.13.024]
WU Gang,YUAN Hua-bing.Study on the Effect of Aprepitant on Improving CINV in Patients with
Stage III~IV Intracranial Glioma[J].Medical Information,2019,32(13):87.[doi:10.3969/j.issn.1006-1959.2019.13.024]
[2]张 诚,丁建玲,麦麦提依明·托合提,等.P53、EGFR在胶质瘤组织中的表达及意义[J].医学信息,2020,33(07):94.[doi:10.3969/j.issn.1006-1959.2020.07.026]
ZHANG Cheng,DING Jian-ling,McMatti Yiming Tohetti,et al.Expression and Significance of P53 and EGFR in Glioma Tissues[J].Medical Information,2020,33(13):94.[doi:10.3969/j.issn.1006-1959.2020.07.026]
[3]程 哲,汪潮潮,吴 娟,等.BFAR在胶质瘤中的表达及其与胶质瘤预后的关系[J].医学信息,2021,34(07):78.[doi:10.3969/j.issn.1006-1959.2021.07.021]
CHENG Zhe,WANG Chao-chao,WU Juan,et al.The Expression of BFAR in Glioma and Its Relationship with the Prognosis of Glioma[J].Medical Information,2021,34(13):78.[doi:10.3969/j.issn.1006-1959.2021.07.021]
[4]刘钰婵,张 威,邱 俊,等.感兴趣区选取数量对脑胶质瘤IVIM参数测量的影响[J].医学信息,2022,35(01):84.[doi:10.3969/j.issn.1006-1959.2022.01.020]
LIU Yu-chan,ZHANG Wei,QIU Jun,et al.The Influence of the Number of Selected ROIs on the Measurement of IVIM Parameters of Glioma[J].Medical Information,2022,35(13):84.[doi:10.3969/j.issn.1006-1959.2022.01.020]
[5]张 群,田秋思,唐铖铖,等.基于生物信息学检测NSUN2基因在胶质瘤中的表达及临床意义[J].医学信息,2022,35(04):1.[doi:10.3969/j.issn.1006-1959.2022.04.001]
ZHANG Qun,TIAN Qiu-si,TANG Cheng-cheng,et al.Detection of NSUN2 Gene Expression in Glioma Based on Bioinformatics and its Clinical Significance[J].Medical Information,2022,35(13):1.[doi:10.3969/j.issn.1006-1959.2022.04.001]
[6]谢 炯,戚 继.PEX基因转染人脐带间充质干细胞的体外培养及鉴定[J].医学信息,2023,36(10):88.[doi:10.3969/j.issn.1006-1959.2023.10.020]
XIE Jiong,QI Ji.In Vitro Culture and Identificationg of Human Umbilical Cord Mesenchymal Stem Cells Modified by PEX Gene[J].Medical Information,2023,36(13):88.[doi:10.3969/j.issn.1006-1959.2023.10.020]
[7]胡彩虹,王志浩,方思琪,等.CARM1在胶质瘤发生发展中的作用研究[J].医学信息,2022,35(06):77.[doi:10.3969/j.issn.1006-1959.2022.06.019]
HU Cai-hong,WANG Zhi-hao,FANG Si-qi,et al.The Role of CARM1 in the Development of Glioma[J].Medical Information,2022,35(13):77.[doi:10.3969/j.issn.1006-1959.2022.06.019]